FDA Seeks Input on Improving Access to Nonprescription Medications
Published Date: 12/2/2025
Notice
Summary
The FDA wants your ideas on how to make it easier for people to get nonprescription drugs, like over-the-counter medicines. They’re gathering feedback now to help plan a public meeting in 2026. If you have thoughts, send them by February 2, 2026—this could lead to faster, cheaper access for everyone!
Analyzed Economic Effects
2 provisions identified: 1 benefits, 1 costs, 0 mixed.
NDA pathway requires consumer-use studies
If you seek to market a nonprescription drug via a new drug application (NDA) under section 505, you must submit adequate tests and substantial evidence that the drug is safe and effective for self-use. FDA often requires consumer studies—such as label comprehension, self-selection, actual use, and human factors studies—and typically requires more data when less is known about nonprescription use.
Public input open — comments due Feb 2, 2026
The FDA is asking the public—drug developers, health care providers, and consumers—to send ideas on how to increase access to nonprescription (over-the-counter) drugs. You can submit electronic or written comments that must be received by February 2, 2026; FDA will use the feedback to plan a public meeting in calendar year 2026.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-06478 — Determination of Regulatory Review Period for Purposes of Patent Extension; VYLOY
The FDA has officially set the review period for VYLOY, a human biological product, so its patent holder can apply for extra patent time. This affects the company behind VYLOY, giving them a chance to extend their patent protection and potentially boost profits. If anyone thinks the dates are wrong or wants to challenge the company’s review speed, they must act by June 2 or September 30, 2026.
2026-06481 — Determination of Regulatory Review Period for Purposes of Patent Extension; HYMPAVZI
The FDA has set the official review period for HYMPAVZI, a new human biological product, so its patent holder can apply for extra patent time. This affects the company behind HYMPAVZI and anyone interested in patent extensions. If you think the dates are wrong or want to challenge the company’s diligence, you have until June 2 or September 30, 2026, to speak up—potentially impacting patent length and market exclusivity.
2026-06480 — Determination of Regulatory Review Period for Purposes of Patent Extension; EMRELIS
The FDA has officially set the review period for EMRELIS, a medicine patent, so the patent owner can apply for extra protection time. If anyone thinks the dates are wrong, they have until June 2, 2026, to speak up. Also, people can challenge whether the patent owner was diligent during the review by September 30, 2026. This affects patent holders and could impact how long they keep exclusive rights to their product.
2026-06479 — Determination of Regulatory Review Period for Purposes of Patent Extension; ENFLONSIA
The FDA has set the official review period for ENFLONSIA, a human biological product, so its patent holder can apply for extra patent time. This affects the company behind ENFLONSIA and anyone interested in patent rules. If you think the dates are wrong or want to challenge the company’s review speed, you have until June 2 or September 30, 2026, to speak up—potentially impacting patent length and market exclusivity.
2026-06477 — Determination of Regulatory Review Period for Purposes of Patent Extension; ENCELTO
The FDA has officially set the review period for ENCELTO, a medicine patent, so the company can apply to extend its patent protection. This affects the drug maker by potentially giving them more time to exclusively sell ENCELTO, which can mean more money. If anyone thinks the dates are wrong or the company wasn’t diligent, they have until June 2 or September 30, 2026, to speak up.
2026-06483 — Determination of Regulatory Review Period for Purposes of Patent Extension; INJECTAFER
The FDA has officially set the review period for INJECTAFER, a drug patent up for extension. This means the company can apply to extend their patent protection, potentially keeping their exclusive rights longer and impacting competition and pricing. If anyone thinks the dates are wrong or the company wasn’t diligent, they can speak up by June 2 or September 30, 2026.
Previous / Next Documents
Previous: 2025-21727 — Combined Notice of Filings #1
The Federal Energy Regulatory Commission got several filings from energy companies like Public Service Company of New Mexico and Aron Energy Prepay LLCs about updates to electric rates and company status. These changes could affect how energy prices and rules work, with some updates set to take effect as soon as May or August 2025. If you want to comment, deadlines are coming up fast in November and December 2025.
Next: 2025-21729 — Records Governing Off-the-Record Communications; Public Notice
The Federal Energy Regulatory Commission (FERC) is sharing updates about off-the-record communications in ongoing cases. They remind everyone that some secret chats can’t affect decisions unless fairness calls for it, while others are part of the official record. This keeps the process fair and transparent, with no new costs or deadlines announced.
Take It Personal
Get Your Personalized Policy View
Start a Free Government Policy Watch to see how policy affects your household, then upgrade to PRIA Full Coverage for year-round monitoring.
Already have an account? Sign in